3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
3
Not yet recruiting
2
Terminated
1
Recruiting
1
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Recurrence
2
Lymphoma, Large B-Cell, Diffuse
2
Pyloric Stenosis, Hypertrophic
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Mantle-Cell
1
Lymphoma
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Leukemia
1
Burkitt Lymphoma
1
Interventions
Rituximab
58
Cyclophosphamide
40
fludarabine phosphate
27
fludarabine
21
Lenalidomide
19
Mycophenolic Acid
17
idelalisib
16
Antilymphocyte Serum
16
Cyclosporine
15
Tacrolimus
13
Radiotherapy
13
Filgrastim
13
venetoclax
12
umbralisib
12
Whole-Body Irradiation
12
Busulfan
12
Bendamustine Hydrochloride
12
ublituximab
11
ibrutinib
11
Methotrexate
11
Peripheral Blood Stem Cell Transplantation
10
Alemtuzumab
10
obinutuzumab
9
Melphalan
9
Chlorambucil
8
Bortezomib
8
thymoglobulin
7
ofatumumab
7
Etoposide
7
Clofarabine
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Leukemia, Lymphocytic, Chronic, B-Cell
×
tafasitamab
×
Clear all
NCT04809467
2026-02-04
topMIND
Incyte Corporation
Phase 1/2
Terminated
54 enrolled
23 charts